We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dried Blood Spots Detect Clonal B-Cell Populations

By LabMedica International staff writers
Posted on 14 Oct 2013
The reliability of lymphoma diagnoses is strikingly different between developed and developing countries due to lack of access to advanced techniques.

Molecular methods are important tools for diagnosis and monitoring of many lymphoproliferative disorders, and new application of dried blood spots (DBS) for detecting clonal B-cell populations in peripheral blood (PB) has been proposed.

Image: The automated MagNA Pure Compact instrument (Photo courtesy of Roche Applied Science).
Image: The automated MagNA Pure Compact instrument (Photo courtesy of Roche Applied Science).

Scientists at the University of Padua (Italy) obtained blood samples from six patients with B-cell chronic lymphocytic leukemia (B-CLL) and five consenting healthy volunteer donors. Dried blood spot samples from African children with non-Hodgkin's lymphoma (NHL) were also analyzed.

Genomic DNA was isolated with the automated MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA) The extracted DNA samples were tested for B-cell immunoglobulin heavy chain (IGH) clonality with the IGH gene clonality assay (Invivoscribe Technologies; San Diego, CA, USA), containing BIOMED-2 primers, positive and negative controls.

The Namalwa B-cell line was used to establish that the assay was sensitive enough to detect 200 clonal cells in the analyzed sample. Very similar clonal results were obtained between DNA from DBS and fresh whole blood from patients with B-cell chronic lymphocytic leukemia. B-cell clonality can also be detected in DBS from African children with Epstein-Barr Virus (EBV)-associated diseases.

DBS cards are a feasible alternative for diagnosing and monitoring various diseases in the developing world. DBS sampling was also suitable to verify the presence of B-cell clonal populations circulating in the blood by immunoglobulin gene rearrangement analysis, with a view to offering molecular evaluation to the diagnosis and monitoring of lymphoproliferative diseases in resource-limited settings.

A diagnosis of leukemia is not usually problematic as immunophenotyping and cytogenetic analysis and histochemical staining can establish diagnosis in virtually all leukemia cases. However, a diagnosis of leukemia may sometimes be more complicated, and molecular clonality evaluation is thought to produce valuable additional information. DBS cards may be useful tools when the molecular analyses complementary to histomorphological/immunophenotypic evaluation are not available. The study was published in the October 2013 issue of the journal Leukemia Research.

Related Links:
University of Padua
Roche Applied Science
Invivoscribe Technologies



New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Latest Hematology News

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients